SEC Form 4 · accession 0001780030-26-000006

Faeth Therapeutics, Inc. · FTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Brian C Stephenson

Officer — Chief Financial Officer

Period of report

Jun 29, 2026

Accepted (ET)

Jul 1, 2026 · 8:09 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001829802

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 29, 2026	P	831	$23.34	A	33,885	I	See footnote
Common Stock^F3,F2	Jun 30, 2026	P	1,910	$22.95	A	35,795	I	See footnote
Common Stock^F4,F2	Jun 30, 2026	P	1,638	$23.88	A	37,433	I	See footnote
Common Stock^F5,F2	Jun 30, 2026	P	4,255	$24.98	A	41,688	I	See footnote
Common Stock^F6,F2	Jul 1, 2026	P	4,400	$23.40	A	46,088	I	See footnote
Common Stock^F7,F2	Jul 1, 2026	P	600	$24.22	A	46,688	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F5The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F6The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F7The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.